• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Amylin Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011 Product Image

Amylin Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

  • ID: 1964472
  • November 2011
  • 116 pages
  • Global Markets Direct

Amylin Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Amylin Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Amylin Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Amylin Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Amylin Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Amylin Pharmaceuticals, Inc. - Brief Amylin Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Amylin Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- READ MORE >



List of Tables
List of Figures
Amylin Pharmaceuticals, Inc. Snapshot
Amylin Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Amylin Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Amylin Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Amylin Pharmaceuticals, Inc. – Pipeline Products Glance
Amylin Pharmaceuticals, Inc. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Amylin Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Amylin Pharmaceuticals, Inc. – Drug Profiles
AC2307
Product Description
Mechanism of Action
R&D Progress
Byetta + Avandia
Product Description
Mechanism of Action
R&D Progress
Byetta + Lantus
Product Description
Mechanism of Action
R&D Progress
Exenatide Nasal
Product Description
Mechanism of Action
R&D Progress
Exenatide Suspension
Product Description
Mechanism of Action
R&D Progress
Exenatide Transdermal Patch
Product Description
Mechanism of Action
R&D Progress
Metreleptin
Product Description
Mechanism of Action
R&D Progress
Pramlintide
Product Description
Mechanism of Action
R&D Progress
PYY 3-36 + Pramlintide
Product Description
Mechanism of Action
R&D Progress
Amylin Pharmaceuticals, Inc. – Pipeline Analysis
Amylin Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Amylin Pharmaceuticals, Inc. - Pipeline Products By Target
Amylin Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Amylin Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Amylin Pharmaceuticals, Inc. – Recent Pipeline Updates
Amylin Pharmaceuticals, Inc. - Dormant Projects
Amylin Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AC2307
Metreleptin
Pramlintide + Metreleptin
Amylin Pharmaceuticals, Inc. – Company Statement
Amylin Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2007: Once-Weekly Exenatide Showed Statistical Improvement in Glucose Control Compared to BYETTA.
Mar 30, 2004: Amylin Pharmaceuticals Advances Clinical Pipeline In Diabetes and Obesity
Jul 29, 2003: Amylin Pharmaceuticals Reports Encouraging Phase II Results From GLP-1 Program In Severe Congestive Heart Failure
Apr 29, 2005: Amylin and Lilly Announce FDA Approval of BYETTA (Exenatide) Injection
Jun 28, 2010: Amylin Pharmaceuticals, Inc. And Eli Lilly And Company Declared Results From A Study.
Jun 28, 2010: Eli Lilly And Company Declared Final Results From A Retrospective Study.
Aug 27, 2008: Amylin & Lly Provided Additionla Inforamation For Fda Alert For Byetta.
Jun 26, 2010: Amylin And Lilly Announce Clinical Study Results Of BYETTA In Combination With Lantus In Patients With Type 2 Diabetes
Jun 26, 2010: Amylin And Lilly Announce Study Results Of BYETTA At ADA Annual Meeting
Jun 26, 2010: Amylin Announces SYMLIN Clinical Data For Treatment Of Type 2 Diabetes
Jun 26, 2010: When BYETTA Was Added to Lantus, Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control.
Jun 26, 2006: Nastech Pharmaceutical Company Inc. Enters Into Development And License Agreement With Amylin Pharmaceuticals
Jan 25, 1999: Amylin Pharmaceuticals Announces Additional Data From Long-Term Pramlintide Studies
Jun 24, 2011: Amylin, Eli Lilly And Alkermes Announce Additional Results From Phase II Study Of Exenatide
Jun 24, 2011: Analysis Finds BYETTA Associated With Lower Likelihood Of Heart Failure Compared With Other Diabetes Therapies
Jun 24, 2011: Analysis Provides New Insights Into Use Of Amylin's SYMLIN In Patients With Type 1 Diabetes Using Insulin Pumps
Jun 24, 2011: Retrospective Analysis Finds BYETTA Associated With Lower Likelihood Of Heart Failure Compared With Other Diabetes Therapies
Jun 24, 2007: Study Results showed the Comparison between Insulin and BYETTA in Blood Glucose Control.
Jun 23, 2007: BYETTA Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes, When Treated for Three and Half Years.
Feb 23, 2010: Amylin And Takeda To Advance Development Of Pramlintide/Metreleptin Combination Treatment For Obesity
Dec 22, 2010: Amylin And Lilly Seek Expanded Use Of BYETTA Along With Basal Insulin
Oct 22, 2007: On Amylin's Byetta FDA issued alert due to cause of pancreatitis.
Nov 21, 2008: BYETTA (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
Aug 20, 2008: Amylin Pharmaceuticals Diabetes Drug Byetta the Focused California Lawsuit.
Oct 19, 2011: Lilly And Amylin Announce FDA Approval Of BYETTA For Use With Insulin Glargine
Aug 18, 2008: FDA reported deaths with Byetta diabetes drug.
Nov 17, 2010: Amylin And Eli Lilly Report Study Results Of BYETTA Compared To Other Diabetes Medications In Type 2 Diabetes Patients
Mar 16, 2011: Amylin And Takeda Voluntarily Suspend Clinical Activities In Obesity Trial
Dec 15, 2009: Amylin Pharmaceuticals, Eli Lilly And Alkermes, Inc Announces Positive Clinical Trial Study Results Of BYETTA
Dec 15, 2009: Exenatide Provided Superior Glucose Control Compared to BYETTA.
Nov 15, 2007: Pramlintide And Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss In 24-Week Clinical Obesity Study
Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy
Apr 15, 2011: Lilly Announces BYDUREON Recommended For Approval In Europe
Nov 10, 2009: Fda Added Warning To Byetta Labeling About Renal Failure.
Jul 10, 2007: Scottish Medicines Consortium Accepted Byetta - First in a New Class of Medicines- incretin mimetics, used for the Treatment of Type 2 Diabetes - Before Patients Start Insulin Therapy .
Jun 10, 2006: BYETTA Shown to Reduce Blood Glucose Levels When Added to Patients Using a TZD
Jun 10, 2005: Long-Term Data on BYETTA Show Sustained Improvements in Glucose Control and Progressive Weight Reduction in People with Type 2 Diabetes
Jun 10, 2005: Study Shows BYETTA Improves Blood Sugar Levels as Effectively as Insulin Glargine
May 10, 2011: JDRF And Amylin Partner To Investigate Co-Formulating Two Hormones For Treatment Of Type 1 Diabetes
Sep 09, 2008: First Reported Head-to-Head Study Showed BYETTA (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia (sitagliptin) in Patients With Type 2 Diabetes
Sep 09, 2008: Head-to-Head Study Showed BYETTA(exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia(sitagliptin) in Type 2 Diabetes Patients.
Jul 09, 2009: Amylin Pharmaceuticals Announces Positive Results From Dose-Ranging Clinical Study Of Pramlintide/Metreleptin Combination Treatment For Obesity
Feb 09, 2006: Amylin Pharmaceuticals Announcess Positive Results From Phase II Gose-Ranging Study Of Pramlintide
Feb 09, 2006: Pramlintide Obesity Study Results Positive
Dec 08, 2008: Amylin And Lilly Update on FDA Review of Monothearpy BYETTA(exenatide) Injection.
Jun 07, 2008: Monotherapy BYETTA (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Dec 06, 2007: In Type 2 Diabetes adults, BYETTA(Monotherapy) Showed Significant Improvement in Glucose Control and Weight Loss
Sep 06, 2007: European Commission Approved New Storage Instructions for BYETTA.
May 05, 2008: Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study Of Pramlintide/Metreleptin Combination Treatment In Obesity
Aug 04, 2011: Amylin And Takeda Discontinue Development Of Pramlintide/Metreleptin Combination Treatment For Obesity Following Commercial Reassessment Of Program
Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy
Nov 03, 2009: Lilly (eli) & Company - Statement On Update Of FDA'S Byetta Injection
Jan 03, 2007: FDA Approved BYETTA(exenatide) Injection for Expanded Combination Use
Nov 02, 2009: Eli Lilly And Company Declared That The FDA Has Approved Byetta For Expanded Indication.
Nov 01, 2009: FDA ordered Amylin to revise label for Byetta injection, Which is used to treat Type 2 diabetes to include information on possible risk of kidney problems.
Jun 01, 2005: Byetta, the First incretin mimetic, has got approval for diabetes: exenatide is formulated subcutaneous injection for self-administeration within 1 hour of meals.
Mar 01, 2006: Supplemental New Drug Application Was Submitted to FDA for Use of Byetta With TZDs.
Financial Deals Landscape
Amylin Pharmaceuticals, Inc., Deals Summary
Amylin Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Altea Therapeutics Secures Financing From Amylin And Lilly Ventures
Xenome Raises $10 Million In A Venture Financing Round
Kelaroo Secured Investment From Amylin Pharmaceuticals
Partnerships
Amylin Pharmaceuticals Announces To Terminate Co-Development Agreement With Eli Lilly For Exenatide
Juvenile Diabetes Enters Into Co-Development Agreement With Amylin Pharmaceuticals
BioSeek Enters Into Collaboration With Amylin Pharmaceuticals
Amylin Enters Into Co-Development Agreement With Biocon
Amylin Pharmaceuticals Enters Into An Agreement With Eli Lilly
Altea Therapeutics Enters Into An Agreement With Eli Lily And Amylin Pharmaceuticals
Pacira Pharmaceuticals Enters Into Co-Development Agreement With Amylin Pharmaceuticals
Xenome Signs An Agreement With Amylin Pharmaceuticals
BioSeek Enters Into Research Agreement With Amylin Pharmaceuticals
PsychoGenics Forms Joint Venture With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into An Agreement With Reliant Pharmaceuticals
Biosite Signs Discovery Agreement With Amylin Pharmaceuticals
Licensing Agreements
Kelaroo Expands Its Agreement With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into Licensing Agreement With Amgen
Affibody Enters Into Licensing Agreement With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into Licensing Agreement With Takeda Pharmaceutical
BioSeek Enters Into Licensing Agreement With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into Agreement With Nastech
Diabetica Enters Into Licensing Agreement With Amylin
Equity Offering
Amylin Pharmaceuticals Completes Public Offering Of $535 Million
Amylin Pharmaceuticals Completes Public Offering of $157 Million
Amylin Pharmaceuticals Completes Public Offering Of $202 Million
Debt Offering
Amylin Completes Private Placement Of 3% Convertible Senior Notes For $575 Million
Amylin Pharmaceuticals Completes Private Placement Of Convertible Senior Notes For $200 Million
Acquisition
Asterand Acquires BioSeek
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Amylin Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Amylin Pharmaceuticals, Inc. – Filed, H2 2011
Amylin Pharmaceuticals, Inc. – Phase III, H2 2011
Amylin Pharmaceuticals, Inc. - Phase II, H2 2011
Amylin Pharmaceuticals, Inc. - Phase I, H2 2011
Amylin Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Amylin Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Amylin Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Amylin Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Amylin Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Amylin Pharmaceuticals, Inc., Subsidiaries
Amylin Pharmaceuticals, Inc., Deals Summary
Altea Therapeutics Secures Financing From Amylin And Lilly Ventures
Xenome Raises $10 Million In A Venture Financing Round
Kelaroo Secured Investment From Amylin Pharmaceuticals
Amylin Pharmaceuticals Announces To Terminate Co-Development Agreement With Eli Lilly For Exenatide
Juvenile Diabetes Enters Into Co-Development Agreement With Amylin Pharmaceuticals
BioSeek Enters Into Collaboration With Amylin Pharmaceuticals
Amylin Enters Into Co-Development Agreement With Biocon
Amylin Pharmaceuticals Enters Into An Agreement With Eli Lilly
Altea Therapeutics Enters Into An Agreement With Eli Lily And Amylin Pharmaceuticals
Pacira Pharmaceuticals Enters Into Co-Development Agreement With Amylin Pharmaceuticals
Xenome Signs An Agreement With Amylin Pharmaceuticals
BioSeek Enters Into Research Agreement With Amylin Pharmaceuticals
PsychoGenics Forms Joint Venture With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into An Agreement With Reliant Pharmaceuticals
Biosite Signs Discovery Agreement With Amylin Pharmaceuticals
Kelaroo Expands Its Agreement With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into Licensing Agreement With Amgen
Affibody Enters Into Licensing Agreement With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into Licensing Agreement With Takeda Pharmaceutical
BioSeek Enters Into Licensing Agreement With Amylin Pharmaceuticals
Amylin Pharmaceuticals Enters Into Agreement With Nastech
Diabetica Enters Into Licensing Agreement With Amylin
Amylin Pharmaceuticals Completes Public Offering Of $535 Million
Amylin Pharmaceuticals Completes Public Offering of $157 Million
Amylin Pharmaceuticals Completes Public Offering Of $202 Million
Amylin Completes Private Placement Of 3% Convertible Senior Notes For $575 Million
Amylin Pharmaceuticals Completes Private Placement Of Convertible Senior Notes For $200 Million
Asterand Acquires BioSeek

List of Figures
Amylin Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, H2 2011
Amylin Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Amylin Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos